HRP20220811T1 - Agonistička sredstva za vezanje tnf receptora - Google Patents

Agonistička sredstva za vezanje tnf receptora Download PDF

Info

Publication number
HRP20220811T1
HRP20220811T1 HRP20220811TT HRP20220811T HRP20220811T1 HR P20220811 T1 HRP20220811 T1 HR P20220811T1 HR P20220811T T HRP20220811T T HR P20220811TT HR P20220811 T HRP20220811 T HR P20220811T HR P20220811 T1 HRP20220811 T1 HR P20220811T1
Authority
HR
Croatia
Prior art keywords
seq
amino acid
acid sequence
heavy chain
light chain
Prior art date
Application number
HRP20220811TT
Other languages
English (en)
Inventor
Ugur Sahin
Friederike GIESEKE
Isil Altintas
David Satijn
Paul Parren
Original Assignee
BioNTech SE
Genmab A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Genmab A/S filed Critical BioNTech SE
Publication of HRP20220811T1 publication Critical patent/HRP20220811T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Claims (10)

1. Bispecifično antitijelo koje sadrži najmanje dvije vezne domene, pri čemu se prva vezna domena veže za prvi receptor superfamilije faktora nekroze tumora (TNF), i druga vezna domena se veže za drugi receptor superfamilije TNF, gdje prva vezna domena koji se veže za CD40 sadrži (a) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2323, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2324 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2325, i regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2326, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2327 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2328; ili (b) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2321 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2322 i gdje druga vezna domena koji se veže za 4-1BB (CD137) sadrži (a) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2297, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2298 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2299, i regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2300, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2301 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2302; (b) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2241 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2242; (c) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2255, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2256 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2257, i regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2258, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2259 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2260; (d) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2227 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2228; (e) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2315, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2316 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2317, i regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2318, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2319 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2320; ili (f) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2247 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2248.
2. Bispecifično antitijelo prema patentnom zahtjevu 1, koje je u formatu antitijela pune dužine.
3. Bispecifično antitijelo prema patentnim zahtjevima 1 ili 2, koje sadrži jednu ili više konstantnih domena teškog lanca imunoglobulina i/ili konstantnih domena lakog lanca imunoglobulina.
4. Molekula nukleinske kiseline koja kodira bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu je, poželjno, molekula nukleinske kiseline sadržana u vektoru.
5. Stanica koja sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 4.
6. Farmaceutska kompozicija koja sadrži, kao aktivno sredstvo, bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, ili stanicu prema patentnom zahtjevu 5.
7. Farmaceutska kompozicija prema patentnom zahtjevu 6, koja dodatno sadrži farmaceutski prihvatljiv nosač i/ili ekscipijens.
8. Komplet koji sadrži bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, stanicu prema patentnom zahtjevu 5, ili farmaceutsku kompoziciju prema patentnom zahtjevu 6 ili 7.
9. Bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, stanica prema patentnom zahtjevu 5, ili farmaceutska kompozicija prema patentnom zahtjevu 6 ili 7 za uporabu kao lijek.
10. Bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, stanica prema patentnom zahtjevu 5, ili farmaceutska kompozicija prema patentnom zahtjevu 6 ili 7 za uporabu u liječenju bolesti odabrane iz grupe koja se sastoji od raka, infektivnih bolesti, upalnih bolesti, metaboličkih bolesti, autoimunih poremećaja i odbacivanja transplantata.
HRP20220811TT 2015-01-08 2016-01-08 Agonistička sredstva za vezanje tnf receptora HRP20220811T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015050255 2015-01-08
EP19194817.3A EP3623386B1 (en) 2015-01-08 2016-01-08 Agonistic tnf receptor binding agents

Publications (1)

Publication Number Publication Date
HRP20220811T1 true HRP20220811T1 (hr) 2022-09-30

Family

ID=55072677

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20220811TT HRP20220811T1 (hr) 2015-01-08 2016-01-08 Agonistička sredstva za vezanje tnf receptora
HRP20191824TT HRP20191824T1 (hr) 2015-01-08 2019-10-09 Agonistička sredstva za vezivanje tnf receptora

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20191824TT HRP20191824T1 (hr) 2015-01-08 2019-10-09 Agonistička sredstva za vezivanje tnf receptora

Country Status (24)

Country Link
US (3) US10457735B2 (hr)
EP (3) EP3623386B1 (hr)
JP (4) JP6744326B2 (hr)
KR (3) KR102238326B1 (hr)
CN (3) CN111499752A (hr)
AU (2) AU2016205974B2 (hr)
BR (1) BR112017013189B1 (hr)
CA (2) CA2969888A1 (hr)
CY (1) CY1122399T1 (hr)
DK (2) DK3242890T3 (hr)
ES (2) ES2755527T3 (hr)
HR (2) HRP20220811T1 (hr)
HU (2) HUE048532T2 (hr)
LT (1) LT3623386T (hr)
ME (1) ME03576B (hr)
MX (2) MX2017008917A (hr)
PL (2) PL3242890T3 (hr)
PT (2) PT3242890T (hr)
RS (2) RS63384B1 (hr)
RU (2) RU2020115901A (hr)
SG (2) SG11201704597WA (hr)
SI (2) SI3242890T1 (hr)
WO (1) WO2016110584A1 (hr)
ZA (1) ZA201704797B (hr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110981964B (zh) 2013-01-14 2023-09-15 Xencor股份有限公司 新型异二聚体蛋白
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
KR102497443B1 (ko) 2014-03-28 2023-02-08 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
PE20171103A1 (es) 2014-11-26 2017-08-07 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38
KR20180015650A (ko) 2015-05-07 2018-02-13 아게누스 인코포레이티드 항-ox40 항체 및 이의 사용 방법
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
KR102426765B1 (ko) * 2016-04-22 2022-07-29 엘리게이터 바이오사이언스 에이비 Cd137에 대한 신규한 이중특이성 폴리펩타이드
RU2022104399A (ru) 2016-06-14 2022-05-05 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
AU2017290086A1 (en) 2016-06-28 2019-01-24 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US11091557B2 (en) * 2016-07-14 2021-08-17 Genmab A/S Methods of producing multispecific antibodies against CD40 and CD137
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3035343A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP7305538B2 (ja) 2016-09-23 2023-07-10 メルス ナムローゼ フェンノートシャップ 細胞によって発現される生物活性を調節する結合分子
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
IL268058B2 (en) 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for depleting cd137 plus cells
CA3055433A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Humanized anti-cd40 antibodies
WO2019016402A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO
SG11202000198QA (en) * 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3676294A4 (en) * 2017-08-28 2021-12-22 Systimmune, Inc. ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗pd−1配列を用いた二重特異性および単一特異性抗体
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたil−2 fc融合タンパク質
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
EP3781599A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CN113454111A (zh) 2018-11-06 2021-09-28 健玛保 抗体配制剂
US20220332800A1 (en) 2018-11-20 2022-10-20 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
CA3132185A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
CA3137373A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
CA3169963A1 (en) 2020-02-04 2021-08-12 Genmab A/S Antibodies for use in therapy
WO2021202807A1 (en) * 2020-03-31 2021-10-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Proteomic screening for lysosomal storage diseases
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CN112175080B (zh) * 2020-10-22 2021-05-25 优睿赛思(武汉)生物科技有限公司 抗人白介素-6高亲和力兔单克隆抗体及应用
IL303424A (en) 2020-12-07 2023-08-01 Genmab As Combined treatment with antibodies and taxane
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509915A (ja) * 2021-03-09 2024-03-05 ジェンマブ エー/エス 治療におけるcd40およびcd137に対する多重特異性結合物質
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
AU2022255506A1 (en) 2021-04-08 2023-11-09 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
BR112023027006A2 (pt) 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
WO2024050318A1 (en) * 2022-08-27 2024-03-07 H. Lee Moffitt Cancer Center And Research Institute Cd40l 41bbl bispecific proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2467242A1 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
CN101023102B (zh) * 2004-09-17 2013-05-29 霍夫曼-拉罗奇有限公司 抗-ox40l抗体
WO2007109254A2 (en) * 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
PL2201100T3 (pl) * 2007-09-14 2016-10-31 Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu
PT2594590E (pt) * 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
AU2011275749C1 (en) 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
CN103347898B (zh) 2011-01-10 2017-12-05 Ct大西洋有限公司 包括与肿瘤相关抗原结合抗体的联合治疗
AU2012299421B2 (en) * 2011-08-23 2016-02-04 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
SG11201507781VA (en) * 2013-03-18 2015-10-29 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
US11091557B2 (en) * 2016-07-14 2021-08-17 Genmab A/S Methods of producing multispecific antibodies against CD40 and CD137

Also Published As

Publication number Publication date
SI3623386T1 (sl) 2022-09-30
US20200079866A1 (en) 2020-03-12
RU2020115901A (ru) 2020-08-05
RS59693B1 (sr) 2020-01-31
KR20240028548A (ko) 2024-03-05
NZ733157A (en) 2021-10-29
CA2969888A1 (en) 2016-07-14
CN109476761A (zh) 2019-03-15
CA3224830A1 (en) 2016-07-14
SI3242890T1 (sl) 2020-01-31
CY1122399T1 (el) 2020-11-25
EP4071176A2 (en) 2022-10-12
MX2017008917A (es) 2018-02-09
KR102238326B1 (ko) 2021-04-12
US20180194849A1 (en) 2018-07-12
DK3242890T3 (da) 2019-10-21
EP3242890A1 (en) 2017-11-15
PL3623386T3 (pl) 2022-08-08
MX2020012240A (es) 2021-02-22
LT3623386T (lt) 2022-08-10
SG10202003171TA (en) 2020-05-28
JP2022025064A (ja) 2022-02-09
CN111499752A (zh) 2020-08-07
ES2755527T3 (es) 2020-04-22
JP6950056B2 (ja) 2021-10-13
ZA201704797B (en) 2019-05-29
US11814411B2 (en) 2023-11-14
HUE048532T2 (hu) 2020-07-28
RU2017127792A (ru) 2019-02-08
KR20170132717A (ko) 2017-12-04
KR20210041634A (ko) 2021-04-15
EP4071176A3 (en) 2022-12-14
DK3623386T3 (da) 2022-07-04
AU2016205974A1 (en) 2017-07-13
AU2022200571A1 (en) 2022-02-17
EP3623386B1 (en) 2022-04-13
RS63384B1 (sr) 2022-08-31
US20210253725A1 (en) 2021-08-19
SG11201704597WA (en) 2017-07-28
RU2017127792A3 (hr) 2019-06-17
EP3242890B1 (en) 2019-09-04
PT3242890T (pt) 2019-12-10
BR112017013189A2 (pt) 2018-04-10
JP2020188797A (ja) 2020-11-26
ES2922398T3 (es) 2022-09-14
EP3623386A1 (en) 2020-03-18
RU2723131C2 (ru) 2020-06-08
CN109476761B (zh) 2020-01-10
CN117843799A (zh) 2024-04-09
HRP20191824T1 (hr) 2020-01-24
JP2018506298A (ja) 2018-03-08
WO2016110584A1 (en) 2016-07-14
JP6744326B2 (ja) 2020-08-19
ME03576B (me) 2020-07-20
KR102640769B1 (ko) 2024-02-27
PL3242890T3 (pl) 2020-04-30
US10457735B2 (en) 2019-10-29
JP7390345B2 (ja) 2023-12-01
AU2016205974B2 (en) 2021-11-04
HUE059219T2 (hu) 2022-10-28
JP2023085435A (ja) 2023-06-20
US10927181B2 (en) 2021-02-23
PT3623386T (pt) 2022-07-18
BR112017013189B1 (pt) 2024-03-05

Similar Documents

Publication Publication Date Title
HRP20220811T1 (hr) Agonistička sredstva za vezanje tnf receptora
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
JP2022177090A5 (hr)
HRP20180269T1 (hr) Anti-cd40 protutijela, upotrebe i postupci
HRP20170815T1 (hr) Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
HRP20201503T1 (hr) MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79
HRP20201432T1 (hr) Il-17a sredstvo za vezivanje i njegove uporabe
HRP20140108T1 (hr) Protutijela protiv sklerostina
HRP20210393T1 (hr) Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja
HRP20200174T1 (hr) Antitijela antigena 2 anti-krvne dendritične stanice i njihova uporaba
HRP20221041T1 (hr) Anti-pd-1 antitijela i sastavi
JP2015535828A5 (hr)
JP2013121353A5 (hr)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
HRP20191277T1 (hr) Anti-cd26 antitijela i njihove primjene
HRP20171775T1 (hr) Molekule protutijela koje vežu trombin i njihova uporaba
RU2016100892A (ru) Антитела против tweakr и их применение
JP2017113019A5 (hr)
HRP20180776T1 (hr) Antagonisti il17c za liječenje upalnih poremećaja
RU2016138744A (ru) Антитела, фармацевтические композиции и их применения
HRP20221088T1 (hr) Protutijela i postupci uporabe
JP2016512214A5 (hr)
RU2015102069A (ru) Антитела к биотину и способы их применения
CO2018001256A2 (es) Anticuerpos anti-cd154 y métodos para producir los mismos